Floatz logo

Terelizumab

Gastric Cancer

Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityPhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
65/ 100

Competitive context

282 Active assets in the Gastric Cancer cohort.

Asset / SponsorPhaseRating
Rivoceranib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 4BBB
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 4BB
Eloxatin
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
Docetaxel
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

Terelizumab is also rated in:

chemotherapy-induced toxicityDormant
B
Indicative ·
57 / 100
View asset →
ImmunotherapyDormant
CCC
Indicative ·
54 / 100
View asset →
rectal carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →